Laurence T. Maeyens

Laurence T. Maeyens

Auto-generated profile, based on publicly available information

Laurence T. Maeyens

University of Texas at San Antonio

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2026 in Nature Aging
Verified
Journal Article
Closed access
PDF file
LMLaurence T. Maeyens
Laurence T. Maeyens
JNJames F. Nelson
James F. Nelson
SZShangang Zhao
Shangang Zhao

17 September 2025 in Aging Cell
Verified
Journal Article
Open access
NJNisi Jiang
Nisi Jiang
JYJiyuan Yin
Jiyuan Yin
NLNoah Lawrence
Noah Lawrence
JMJieyi Meng
Jieyi Meng
LMLaurence T. Maeyens
Laurence T. Maeyens
SZShangang Zhao
Shangang Zhao
GLP‐1‐based therapy is highly effective in combating aging‐associated metabolic diseases. However, the metabolic effects of frequent withdrawal from this therapy in aged, obese mice have not been previously studied. In this study, aged obese UM‐HET3 mice were assigned to three groups: Group 1 received no liraglutide treatment (Lira OFF); Group 2 underwent 3 cycles of treatment followed by withdrawal (Lira ON/OFF); and Group 3 remained on continuous treatment (Lira ON). As expected, mice in Group 3 showed reduced body weight and food intake, along with improved metabolic health. In contrast, mice in Group 2 developed hyperleptinemia and visceral fat expansion, leading to impaired metabolic health. Importantly, although these mice regained their fat mass after each treatment cycle, they failed to restore lean mass, an unfavorable shift in body composition that may increase vulnerability to aging‐related sarcopenia. These findings suggest that continuous GLP‐1‐based therapy is necessary to sustain metabolic benefits, while intermittent use may promote age‐associated sarcopenia and metabolic decline.

25 June 2026 in Microbiology and Molecular Biology Reviews
Verified
Journal Article
Closed access
JDJelle Dillen
Jelle Dillen
LMLaurence T. Maeyens
Laurence T. Maeyens
CHColin Hill
Colin Hill
SLSarah Lebeer
Sarah Lebeer
SUMMARY: Many gram-positive bacteria, particularly those within the family Lactobacillaceae, possess significant biotechnological potential across food, feed, supplement, pharmaceutical, and agricultural sectors. Numerous species produce bacteriocins or ribosomally synthesized antimicrobial peptides, some of which undergo post-translational modifications that may confer a competitive advantage in complex microbial communities. These beneficial properties, along with their capacity to produce such bioactive molecules, make Lactobacillaceae a valuable microbial group with broad application potential. This review provides a comprehensive overview of bacteriocin classes within Lactobacillaceae, detailing their classification, mechanisms of action, and genetic organization. We propose a unified classification system, including an extension of existing classes and a standardized, source-based nomenclature for ribosomally produced and post-translationally modified peptides (RiPPs) and unmodified bacteriocins from gram-positive bacteria to enhance clarity and consistency. While proposed for Lactobacillaceae, our proposal fits within the broader scope of the field for the development of community standards in line with the scope of, for example, the “Minimum Information about a Biosynthetic Gene cluster” (MIBiG) database. We also systematically reviewed all reported bacteriocins within Lactobacillaceae, identifying 474 individual bacteriocins to date. Despite advances in genome and peptidome technologies, most remain only partially characterized. Notably, the majority of producing strains originate from food-related niches, highlighting the untapped potential of species from underexplored environments. Given the growing threat of antibiotic resistance and the demand for natural food preservatives, there is an urgent need to fully characterize these bioactive molecules and discover new ones from lesser-studied Lactobacillaceae species for future applications.

22 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LMLaurence T. Maeyens
Laurence T. Maeyens
ALAlison Luciano
Alison Luciano
JNJames F. Nelson
James F. Nelson
GCGary A. Churchill
Gary A. Churchill
Control cohorts anchor the interpretation of lifespan-extending interventions, yet their lifespans vary even under identical experimental conditions. Without quantifying this expected variation, it is difficult to distinguish unusually short- or long-lived cohorts arising by chance from those reflecting potential experimental anomalies, with important consequences for interpreting treatment effects. The National Institute on Aging Interventions Testing Program (ITP), which tests interventions in mice across three independent sites using standardized protocols, provides a unique opportunity to address this problem. Previously, unusually short-lived males at the University of Texas in 2017 and unusually long-lived females at The Jackson Laboratory in 2022 were identified as potentially anomalous, but no standardized framework existed to determine whether such deviations exceeded expected variation. Here, we analyzed 10,757 control mice spanning 18 years of the ITP to quantify historical variation within and between sites and develop a prediction-interval framework for prospectively identifying unusual cohorts. We found that year-to-year variation, particularly in males, contributed substantially more to variation among cohort means than expected from random sampling alone. Accounting for this variation, our predictive framework flagged the 2022 Jackson Laboratory females but not 2017 University of Texas males, while flagging a previously unrecognized male cohort. Excluding this newly flagged cohort from the original lifespan analysis changed the statistical significance of two rapamycin regimens. These findings highlight the importance of a standardized framework for outlier detection and demonstrate the importance of accounting for natural variability in aging studies.

24 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LMLaurence T. Maeyens
Laurence T. Maeyens
NJNisi Jiang
Nisi Jiang
ZXZiying Xu
Ziying Xu
VDVivian Diaz
Vivian Diaz
RSRandy Strong
Randy Strong
JNJames F. Nelson
James F. Nelson
Men live shorter lives than women across nearly all human populations, a disadvantage that extends across most biological causes of death and that cannot be fully explained by behavioral or environmental differences. This suggests that fundamental biological mechanisms contribute to elevated male mortality. Our previous work implicated testicular factors as a major contributor, showing that prepubertal castration extends male lifespan to that of females in UM-HET3 mice, a genetically heterogeneous stock. However, it remains unknown when testicular factors begin to exert their detrimental effects on mortality. Here, we castrated UM-HET3 males before puberty (20 days), after puberty (60 days), or immediately before the typical rise in male mortality (240 days). Castration at all three ages prevented the early male mortality and increased median lifespan by 19.3%, 25.8%, and 32.9%, respectively. The comparable survival benefits of prepubertal and postpubertal castration indicate that exposure to the pubertal surge in testicular factors, including male sex hormones, is not responsible for establishing the male longevity disadvantage. Remarkably, castration at 240 days not only preserved the survival benefit of earlier castration but produced significantly greater survival than earlier castration, suggesting that testicular exposure before 240 days is actually beneficial. The immediate prevention of excess male mortality following castration at 240 days also indicates that the responsible testicular factors act rapidly and that their continued presence is necessary to sustain elevated male mortality. Longitudinal body-composition measurements further revealed that castration shifted males toward a female-like phenotype, characterized by reduced lean mass and continued fat accumulation into later life. Our findings reveal opposing age-dependent effects of testicular factors on survival and narrow the potential therapeutic window to later adulthood.

3 August 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
GLGuannan Li
Guannan Li
LMLaurence T. Maeyens
Laurence T. Maeyens
JYJiyuan Yin
Jiyuan Yin
JFJan-Bernd Funcke
Jan-Bernd Funcke
CJChanmin Joung
Chanmin Joung
SZShangang Zhao
Shangang Zhao
The enzymatic role of ABHD6 in insulin secretion and resistance is well documented. However, its non-enzymatic function, especially its effects on metabolic health, including selective hepatic insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD), is poorly understood. To define the role of ABHD6 in liver physiology, we generated liver-specific ABHD6 knockout mice, as well as liver-specific native and enzymatically inactive mutant ABHD6 overexpression mouse models. We demonstrate that non-enzymatic ABHD6 contributes to the regulation of selective hepatic insulin resistance and MASLD progression. Mechanistically, we show that ABHD6 localizes to the nucleus and interacts with Akt/FoxO1 axis to regulate insulin signaling. Our findings identify a mechanism underlying selective hepatic insulin resistance and highlight a role for the non-enzymatic function of ABHD6 in this process. This study suggests that modulation of this non-enzymatic activity may represent a potential therapeutic strategy for improving metabolic health.